bluebird bio and Five Prime Therapeutics enter into license agreement for novel antibodies
bluebird bio and Five Prime Therapeutics announced an exclusive license agreement to research, develop and commercialize chimeric antigen receptor T cell therapies using Five Prime's proprietary human antibodies to an undisclosed cancer target for hematologic malignancies and solid tumors. May 26, 2015